Bruker announces proteome atlas: Bruker stock gains 1.14 percent

Published on 10/07/2026 at 08:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A plasma proteome atlas was disclosed on October 6, 2026. Bruker stock costs EUR 53.90 on October 7, 2026 after EUR 53.29, plus 1.14 percent.

BRKR, US1167941087, Illustration mit AI erstellt.

Bruker Corporation (US1167941087) was trading at EUR 53.90 at Lang & Schwarz on October 7, 2026 at 8:16 a.m. CEST, up 1.14 percent from the EUR 53.29 prior close. The company also announced a draft atlas of the human plasma proteome on October 6, 2026, as FinanzNachrichten reported.

Proteome research adds a fresh angle

The announcement highlights Bruker's timsTOF mass spectrometry platform and its role in mapping proteins at proteoform resolution. For the stock, the development adds a concrete research application to a portfolio spanning scientific instruments, analytical systems and diagnostic solutions.

Bruker's latest reported operating picture is more measurable. In the second quarter of 2026, reported revenue rose 5.20 percent year over year to USD 838.50 million, according to Yahoo Finance.

Margins and orders carry the story

The same second-quarter 2026 call recorded non-GAAP earnings per share of USD 0.49, up 53.00 percent from USD 0.32 in the second quarter of 2025. Non-GAAP operating margin reached 14.10 percent, while scientific instruments bookings increased 10.00 percent year over year.

That contrast matters: revenue growth was positive, but the earnings improvement was much faster. Bruker said first-half 2026 revenue increased 3.90 percent to USD 1.66 billion, with semiconductor metrology organic revenue growth above 15.00 percent and organic order growth above 30.00 percent.

Fiscal guidance stays measurable

For fiscal 2026, management retained non-GAAP earnings-per-share guidance of USD 2.10 to USD 2.15 and expects reported revenue of USD 3.54 billion to USD 3.57 billion, representing reported growth of 3.00 percent to 4.00 percent versus fiscal 2025. The company also expects non-GAAP operating margin expansion of 250 to 300 basis points year over year.

The near-term setup is uneven. Management said USD 20.00 million of previously planned third-quarter revenue would shift into the fourth quarter because of semiconductor customer delivery timing, while the fourth quarter is expected to benefit from stronger volume and mix.

Bruker stock remains below its yearly high

Bruker stock was trading at EUR 53.90 at Lang & Schwarz on October 7, 2026 at 8:16 a.m. CEST, plus 1.14 percent versus the EUR 53.29 prior close. The primary Nasdaq listing had a 52-week range of USD 32.37 to USD 66.98 and a market capitalization of USD 9.20 billion as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Bruker stock.